1An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ≤40 years at breast cancer diagnosisBritish Journal of Cancer  Clinical Article
2Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesAnnals of Oncology  Clinical Article
3Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutationLung Cancer  Clinical Article
4Clinical outcome of patients with pancreatic metastases from renal cell cancerBMC Cancer  Full Text  Clinical Article
5Assessing the role of platinum agents in aggressive breast cancersCurrent Oncology Reports  Clinical Article
6Targeting the androgen receptor in breast cancerCurrent Oncology Reports  Clinical Article
7S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balanceBMC Cancer  Full Text  Clinical Article
8Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencingBMC Cancer  Full Text  Clinical Article
9Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancerBMC Cancer  Full Text  Clinical Article
10NEOSCOPE: A randomised phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinomaBMC Cancer  Full Text  Clinical Article
1Prescription opioid analgesic use among adults: United States, 1999–2012U.S. National Center for Health Statistics News
2Novel precision medicine tool could help personalize cancer treatmentsDana-Farber Cancer Institute
3Cherenkov effect improves radiation therapy for patients with cancerNorris Cotton Cancer Center News
4Quick antibiotics for fever and low neutrophil count reduces PICU needs and mortality of pediatric cancer patientsUniversity of Colorado Health News
5MDs' recommendations on HPV vaccine carry weight with college studentsRoswell Park Cancer Institute News
6How the landscape of the pancreatic cancer genome is coming into viewGarvan Institute of Medical Research News
7TGen study says destroying material that ‘cloaks’ cancer cells could benefit patientsThe Translational Genomics Research Institute News
8Cancer drug first tested in pet dogs begins human trialsUniversity of Illinois Health News
9Moffitt Cancer Center researchers identify protein pathway involved in brain tumor stem cell growthH. Lee Moffitt Cancer Center & Research Institute News
10IU researchers: Pancreatic cancer patients with particular gene signature may benefit from personalized treatmentIndiana University School of Medicine News

Show Me:

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).

CHD7 associated with survival in pancreatic ductal adenocarcinoma patients receiving gemcitabine

As reported in Cancer Research, low CHD7 expression is associated with increased RFS and OS in pancreatic ductal adenocarcinoma patients receiving gemcitabine. There was no association between CHD7 expression and RFS or OS in patients who were not treated with gemcitabine.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocInsufficient protoporphyrin IX accumulation may limit the benefits of fluorescence-guided resection and photodynamic therapy

Clinical Pearl from Smartest Doc(18)F-sodium fluoride PET is likely to replace (18)F-FDG PET in the staging and detection of progression of osseous metastasis associated with prostate cancer.

Clinical Pearl from Smartest DocColorectal cancer incidence is inversely associated with screening rates.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List